Table 1 Baseline characteristics
From: Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure
N | Total N = 294 057 | Low < 3.9 mmol/L n = 7 408 (2.5%) | Normal 3.9–6.0 mmol/L n = 266 943 (90.8%) | IFG 6.1–6.9 mmol/L n = 9 682 (3.3%) | Undiagnosed DM ≥ 7.0 mmol/L n = 5 457 (1.9%) | Diagnosed DM n = 4 567 (1.6%) | |
|---|---|---|---|---|---|---|---|
Age (years) | 294 057 | 47 (40–56) | 43 (36–51) | 47 (39–55) | 54 (46–61) | 57 (49–64) | 53 (45–60) |
Sex, female | 294 057 | 135 562 (46.1) | 4 382 (59.2) | 124 497 (46.6) | 3 300 (34.1) | 1 646 (30.2) | 1 737 (38.0) |
Blue collar worker | 286 058 | 157 549 (55.1) | 4 090 (56.8) | 142 258 (54.7) | 5 464 (58.3) | 3 084 (59.6) | 2 653 (60.1) |
Born in Nordic countries | 294 057 | 270 242 (92.1) | 6854 (92.5) | 245 489 (92.0) | 8 878 (91.7) | 4 884 (89.5) | 4 147 (90.8) |
Referred from occupational health care | 259 549 | 193 573 (74.6) | 5 187 (79.0) | 177 643 (75.4) | 5 585 (65.6) | 2 710 (57.2) | 2 448 (59.9) |
BMI (kg/m2) | 55 390 | 24.0 (21.8–26.5) | 22.4 (20.6–24.6) | 24.0 (21.8–26.3) | 26.5 (24.2–29.5) | 28.0 (25.5–30.9) | 26.6 (23.4–29.8) |
Kidney disease | 294 057 | 288 (0.1) | 9 (0.1) | 257 (0.1) | 9 (0.1) | 2 (0.0) | 11 (0.2) |
Liver disease | 294 057 | 1 102 (0.4) | 38 (0.5) | 862 (0.3) | 65 (0.7) | 51 (0.9) | 86 (1.9) |
Asthma/COPD | 294 057 | 2 026 (0.7) | 63 (0.9) | 1 740 (0.7) | 93 (1.0) | 55 (1.0) | 75 (1.6) |
History of cancer | 294 057 | 6 550 (2.2) | 131 (1.8) | 5 812 (2.2) | 287 (3.0) | 196 (3.6) | 124 (2.7) |
Mitral stenosis | 294 057 | 34 (0) | 0 | 30 (0) | 1 (0) | 2 (0) | 1 (0) |
Mechanical valve-replacement | 294 057 | 25 (0) | 0 | 24 (0) | 1 (0) | 0 | 0 |
Fasting glucose, mmol/L | 294 057 | 4.8 (4.5–5.2) | 3.7 (3.5–3.8) | 4.8 (4.5–5.2) | 6.3 (6.2–6.6) | 8.2 (7.3–10.4) | 8.3 (6.2–11.9) |
Fructosamine, mmol/L | 242 205 | 2.1 (2.0–2.2) | 2.0 (1.9–2.2) | 2.1 (2.0–2.2) | 2.2 (2.0–2.3) | 2.5 (2.2–2.9) | 2.6 (2.3–3.1) |
Total cholesterol, mmol/L | 294 057 | 5.7 (5.0–6.4) | 5.4 (4.7–6.1) | 5.7 (5.0–6.4) | 6.0 (5.3–6.8) | 6.0 (5.3–6.8) | 5.8 (5.0–6.6) |
Triglyceride level, mmol/L | 294 057 | 1.0 (0.7–1.5) | 0.9 (0.6–1.2) | 1.0 (0.7–1.5) | 1.5 (1.0–2.2) | 1.9 (1.3–2.8) | 1.5 (1.0–2.4) |
Apo-B/Apo-A1 ratio | 294 057 | 0.89 (0.71–1.10) | 0.82 (0.67–1.01) | 0.88 (0.71–1.09) | 0.96 (0.79–1.21) | 1.05 (0.85–1.28) | 0.97 (0.78–1.22) |
Haemoglobin, g/L | 73 119 | 141.0 (133.0–150.0) | 138.0 (129.0–147.0) | 141.0 (132.0–150.0) | 146.0 (138.0–154.0) | 149.0 (140.0- 157.0) | 145.0 (136.0–154.0) |
WBC, 10^9/L | 67 806 | 6.1 (5.1–7.4) | 6.1 (5.1–7.6) | 6.1 (5.1–7.3) | 6.6 (5.6–7.9) | 6.9 (5.8–8.3) | 6.6 (5.5–8.0) |
Subjects with eGFR below 60 ml/min/1.73 m2 | 283 448 | 10 173 (3.5) | 180 (2.4) | 8 435 (3.2) | 698 (7.2) | 559 (10.3) | 301 (6.6) |
Uric acid, umol/L | 278 499 | 287.0 (240.0–337.0) | 262.0 (218.0–311.0) | 286.0 (239.0–335.0) | 335.0 (285.0–389.0) | 321.0 (271.0–380.0) | 286.0 (235.0–345.0) |
CRP, mg/L | 139 257 | 4.0 (1.0–6.0) | 3.0 (1.0–6.0) | 4.0 (1.0–6.0) | 4.0 (3.0–7.0) | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) |
Haptoglobin, g/L | 234 448 | 1.0 (0.9–1.2) | 1.0 (0.8–1.2) | 1.0 (0.9–1.2) | 1.1 (1.0–1.4) | 1.2 (1.0–1.4) | 1.1 (0.9–1.3) |